Login to Your Account



Clinic Roundup


Tuesday, January 31, 2012

• Ziopharm Oncology Inc., of New York, said an independent data monitoring committee unanimously recommended continuation of its international, randomized, double-blind, placebo-controlled Phase III trial of palifosfamide (Zymafos, or ZIO-201), dubbed PICASSO 3, in front-line metastatic soft tissue sarcoma – the third such review and recommendation by the committee.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription